WYU-G6
The cell line is not validated yet.
WYUi004-A
General
Cell Line |
|
| hPSCreg name | WYUi004-A |
| Cite as: | WYUi004-A |
| Alternative name(s) |
WYU-G6
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 26th June 2025 |
| User feedback | |
Provider |
|
| Generator |
Wuyi University (WYU)
Contact:
Wuyi University (WYU) |
| Owner | Wuyi University (WYU) |
| Derivation country | China |
External Databases |
|
| BioSamples | SAMEA118448022 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
Additional restrictions:
The agreement to transfer WYUi004-A to a Secondary Recipient must include: (1) a statement naming the NIGMS Human Genetic Cell Repository and GM25256 of the cell line from which WYUi004-A was derived; (2) a statement that the Secondary Recipient must acknowledge the Repository and GM25256 in any publications or presentations based on the utilization of the NIGMS Repository Sample as follows: WYUi004-A was derived from cell line GM25256, WTC-11 from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research; and (3) a statement that WYUi004-A obtained from different sources will not have undergone the standard quality control of the Repository. The terms of the agreement between the investigator who developed WYUi004-A and the Secondary Recipient who obtains WYUi004-A for research purposes must be consistent with NIH’s Simple Letter of Agreement for the Transfer of Materials or the Uniform Biological Material Transfer Agreement. Both of these documents can be found at: http://www.ott.nih.gov/forms-modelagreements# MTACTA. |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Japanese |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA123456 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Unknown |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | Yes |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell line name |
UCSFi001-A Derived from same source line (potentially other lot and donor, see below):
|
| Source cell type |
Synonyms
|
| Source cell origin |
A zone of skin that is part of a lower leg [Automatically generated definition].
Synonyms
|
| Source cell type (free text) | fibroblasts from skin biopsy of the calf. |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | Clones were picked on standard iPSC morphology (i.e. whether they had tightly packed cells in colonies with tight, non-differentiated boundaries), karyotypic stability, expression of pluirpotency markers OCT3/4, SOX2, NANOG, SSEA4, TRA-1-60, and loss of reprogramming vectors. |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Laminin |
| Feeder cells |
No |
| Passage method |
Enzymatically
Accutase
|
| CO2 Concentration | 5 % |
| Medium |
Other medium:
Base medium: StemFit 04
Main protein source: Serum concentration: 0 % |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
In vitro spontaneous differentiation
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.